TLDR Broadcom released the Brocade X8 Directors and G820 56-port switch, the first 128G Fibre Channel platforms designed for AI applications. The platforms feature quantum-resistant 256-bit encryption and post-quantum cryptography to defend against future quantum computing threats. Brocade X8 Directors handle up to 384 ports at 128G, while the G820 offers 56 128G SFP+ ports [...] The post Broadcom (AVGO) Stock Surges on Launch of Industry-First 128G AI Platforms appeared first on Blockonomi.TLDR Broadcom released the Brocade X8 Directors and G820 56-port switch, the first 128G Fibre Channel platforms designed for AI applications. The platforms feature quantum-resistant 256-bit encryption and post-quantum cryptography to defend against future quantum computing threats. Brocade X8 Directors handle up to 384 ports at 128G, while the G820 offers 56 128G SFP+ ports [...] The post Broadcom (AVGO) Stock Surges on Launch of Industry-First 128G AI Platforms appeared first on Blockonomi.

Broadcom (AVGO) Stock Surges on Launch of Industry-First 128G AI Platforms

TLDR

  • Broadcom released the Brocade X8 Directors and G820 56-port switch, the first 128G Fibre Channel platforms designed for AI applications.
  • The platforms feature quantum-resistant 256-bit encryption and post-quantum cryptography to defend against future quantum computing threats.
  • Brocade X8 Directors handle up to 384 ports at 128G, while the G820 offers 56 128G SFP+ ports in a 1U design.
  • Both products are shipping now through partners including Dell, HPE, IBM, Lenovo, and NetApp.
  • Broadcom stock gained 2.8% Wednesday, also lifted by positive sentiment ahead of Nvidia’s earnings.

Broadcom unveiled two new data center products Wednesday targeting the expanding AI infrastructure market. The Brocade X8 Directors and Brocade G820 56-port switch mark the industry’s first 128G Fibre Channel platforms.


AVGO Stock Card
Broadcom Inc., AVGO

The new Gen 8 Fibre Channel portfolio combines performance upgrades with advanced security features. Both platforms include quantum-resistant 256-bit encryption and post-quantum cryptography algorithms. These protections prepare data centers for threats from quantum computers that don’t yet exist at scale.

Dennis Makishima, vice president and general manager of Brocade Storage Networking at Broadcom, said the platforms create a foundation for mission-critical and enterprise AI workloads. The products target organizations running data-intensive applications that require high-speed storage connectivity.

The Brocade X8 Directors scale up to 384 ports operating at 128G speeds. The Brocade G820 switch packs 56 128G SFP+ ports into a compact 1U form factor. Both incorporate embedded SAN AI technology for automated infrastructure management.

Advanced Features for Modern Data Centers

The platforms ship with AI-powered autonomy that adjusts to changing network conditions. SAN Fabric Intelligence delivers end-to-end visibility across storage networks. An Adaptive Traffic Optimizer manages dynamic load balancing automatically.

Major technology vendors have committed to the new platforms. Dell Technologies, H3C, Hitachi Vantara, HPE, IBM, Lenovo, NetApp, and TG Stor all backed the launch. OEM partners will ship the technology to customers throughout the next several quarters.

Stock Movement and Analyst Sentiment

Broadcom shares climbed 2.8% Wednesday afternoon after reaching as high as 5.6% earlier in the session. The stock benefited from both the product announcement and investor optimism surrounding Nvidia’s quarterly results.

The connection between the two companies runs deep. Broadcom supplies connectivity chips and services that allow multiple processors to operate together in servers. Nvidia provides the GPU hardware powering AI data centers. Positive news for Nvidia frequently lifts Broadcom shares.

Broadcom carries a market cap of $1.61 trillion. The company posted revenue growth of 28.01% to $59.93 billion over the last twelve months. Gross profit margins stand at 77.19%.

Wall Street analysts have raised their price targets recently. Jefferies moved its target to $480 based on growth in Broadcom’s ASIC business. Mizuho increased its target to $435 following a deal with Anthropic worth $10 billion. Evercore ISI set a target of $403 after Broadcom announced its OpenAI partnership.

The company also launched the Thor Ultra recently, the first 800G AI Ethernet Network Interface Card. Both products are available immediately through Broadcom and its OEM partners.

The post Broadcom (AVGO) Stock Surges on Launch of Industry-First 128G AI Platforms appeared first on Blockonomi.

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26